Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.05 -1.4%	$1.86	$1.43 ▼ $4.26	$205.84M	1.62	142,695 shs	123,336 shs
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.84 million shs	N/A
CRON Cronos Group	$2.02 -2.4%	$1.98	$1.60 ▼ $2.54	$779.07M	1.03	1.36 million shs	812,345 shs
TRVI Trevi Therapeutics	$6.86 -2.1%	$6.23	$2.36 ▼ $7.48	$804.61M	0.46	1.45 million shs	1.58 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	+1.96%	+4.52%	+6.67%	+37.75%	-42.86%
CMRX Chimerix	0.00%	0.00%	0.00%	-0.12%	+850.47%
CRON Cronos Group	-0.96%	+1.47%	+7.25%	+20.35%	-14.11%
TRVI Trevi Therapeutics	+7.02%	+17.82%	+15.11%	+13.06%	+150.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.2043 of 5 stars	3.5	1.0	0.0	3.6	0.8	0.6
CMRX Chimerix	0.5596 of 5 stars	1.0	0.0	4.1	0.0	1.7	0.6
CRON Cronos Group	1.5958 of 5 stars	0.0	4.0	0.0	1.6	0.0	2.5
TRVI Trevi Therapeutics	3.8886 of 5 stars	4.7	5.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	485.37% Upside
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
CRON Cronos Group	0.00	N/A	N/A	N/A
TRVI Trevi Therapeutics	3.30	Buy	$20.88	204.30% Upside

Current Analyst Ratings Breakdown

Latest ACIU, TRVI, CMRX, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/1/2025	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.64	N/A	N/A	$1.29 per share	1.59
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
CRON Cronos Group	$117.61M	6.62	N/A	N/A	$2.90 per share	0.70
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-177.79%	-44.60%	-22.25%	8/5/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.13	15.54	67.33	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-58.41%	-52.52%	8/6/2025 (Estimated)

Latest ACIU, TRVI, CMRX, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ACIU AC Immune	-$0.18	N/A	N/A	N/A	$1.98 million	N/A
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.53	1.53
CMRX Chimerix	N/A	6.33	6.33
CRON Cronos Group	N/A	27.80	26.75
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CMRX Chimerix	45.42%
CRON Cronos Group	8.71%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CMRX Chimerix	13.10%
CRON Cronos Group	6.90%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
CRON Cronos Group	450	385.68 million	359.07 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

ACIU, TRVI, CMRX, and CRON Headlines

Recent News About These Companies

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

July 11, 2025 | zacks.com

Trevi Therapeutics (NASDAQ:TRVI) Trading 6.1% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TRVI FY2025 Earnings

July 5, 2025 | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 3.7% - Should You Sell?

July 3, 2025 | marketbeat.com

Analysts Offer Predictions for TRVI FY2025 Earnings

July 3, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

July 2, 2025 | msn.com

TRVI Trevi Therapeutics, Inc. - Seeking Alpha

July 1, 2025 | seekingalpha.com

Cantor Fitzgerald Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)

July 1, 2025 | marketbeat.com

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

July 1, 2025 | prnewswire.com

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm

June 26, 2025 | globenewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 4% - Time to Sell?

June 25, 2025 | marketbeat.com

TRVI - Trevi Therapeutics Inc Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, TRVI, CMRX, and CRON Company Descriptions

AC Immune NASDAQ:ACIU

$2.05 -0.03 (-1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 -0.01 (-0.49%)

As of 04:04 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Chimerix NASDAQ:CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Cronos Group NASDAQ:CRON

$2.02 -0.05 (-2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.99%)

As of 06:26 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Trevi Therapeutics NASDAQ:TRVI

$6.86 -0.15 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$6.88 +0.02 (+0.29%)

As of 06:19 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time